NASDAQ:XBIO Xenetic Biosciences Q3 2024 Earnings Report $3.86 +0.04 (+1.05%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Xenetic Biosciences EPS ResultsActual EPS-$0.28Consensus EPS -$0.14Beat/MissMissed by -$0.14One Year Ago EPSN/AXenetic Biosciences Revenue ResultsActual Revenue$0.61 millionExpected Revenue$0.75 millionBeat/MissMissed by -$140.00 thousandYoY Revenue GrowthN/AXenetic Biosciences Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateWednesday, November 13, 2024Conference Call Time7:00AM ETUpcoming EarningsXenetic Biosciences' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly Report(10-Q) Xenetic Biosciences Earnings HeadlinesXenetic Biosciences (NASDAQ:XBIO) Shares Cross Above 50-Day Moving Average - Here's WhyAugust 15, 2026 | americanbankingnews.comXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...June 4, 2026 | finance.yahoo.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 26 at 1:00 AM | Porter & Company (Ad)Xenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comXenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders. At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets. By integrating these platforms, the company aims to create therapeutics with enhanced efficacy, favorable dosing profiles and better patient compliance. Xenetic’s lead programs have progressed through preclinical development and early-stage clinical trials, with an emphasis on oncology immunotherapy and enzyme replacement therapies. The company collaborates with academic institutions and industry partners to advance its candidates and to explore new applications of its delivery and targeting technologies. Research and development activities are centralized in the United States, supported by strategic operations in Europe. Headquartered in Boston, Massachusetts, Xenetic is committed to innovation in biologics and small-molecule therapeutics. Led by a team with deep expertise in protein engineering, drug development and regulatory strategy, the company continues to build a pipeline aimed at improving outcomes for patients with serious and life-threatening conditions. Xenetic Biosciences is publicly traded on the NASDAQ under the ticker XBIO.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-RaisePhotronics Is Quietly Becoming a Key Winner From the AI BoomOpenAI’s Jalapeño Chip Could Change the AI Hardware RaceHONA: The Spin-Off Story the Market Is Reading WrongPDD Beat Earnings—So Why Did the Stock Still Fall?Marzetti Stock Confirms Reversal on Earnings Strength, Dividend GrowthDICK's Sporting Goods Faces Pain Now for a Bigger Prize Upcoming Earnings Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
